Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

KZIA stock hub

Kazia Therapeutics Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

KZIAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

165M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

KZIA

In the news

Latest news · KZIA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-106.9

P25 -105.6P50 -46.5P75 -3.1

ROIC-53.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All KZIA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

201

Groups with data

Currency

AUD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001055886
Company name	Kazia Therapeutics Limited
Country	Australia
Country code	US
Cusip	48669G303
Employees	6
Employees Change	-0.8%
Employees Change Percent	-11.76
Enterprise value	$118.7M
Exchange	NASDAQ
Financial currency	AUD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	1999-01-06
Isin	US48669G3039
Last refreshed	2026-05-10
Market cap	$165M
Market cap category	Micro-Cap
Price	$14.44
Price currency	USD
Rev Per Employee	211,071.5x
Sector	Healthcare
Sic	8880
Symbol	KZIA
Website	https://www.kaziatherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-9.22%
EV Sales Forward	755.91x
EV/Sales	93.76x
FCF yield	-6.33%
P/B ratio	5.28x
P/S ratio	130.29x
PS Forward	1,050.45x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$1.3M
Gross Profit Growth	-24.15%
Gross Profit Growth Q	1,838,320%
Gross Profit Growth5 Y	39.18%
Net Income	$-15.2M
Net Income Growth Years	1%
Pretax Margin	-1,285.72%
Profit Per Employee	$-2.5M
ROA	-25.7
Roa5y	-45.34
ROCE	-39.17
ROE	-106.9
ROIC	-53.34

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-28.44%
Cagr15y	-20.76%
Cagr1y	360.35%
Cagr20y	-24.69%
Cagr3y	-38.13%
Cagr5y	-50.84%
EPS Growth Years	3
Revenue Growth	-24.15x
Revenue Growth Q	312.39x
Revenue Growth Years	0x
Revenue Growth5 Y	39.18x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.04
Assets	$47.4M
Cash	$46.3M
Current Assets	$50.7M
Current Liabilities	$17.7M
Debt	$65,906
Debt Equity	$0
Equity	$31M
Liabilities	$16.4M
Long Term Assets	$-3.3M
Long Term Liabilities	$-1.2M
Net Cash	$46.3M
Net Cash By Market Cap	$28.04
Net Cash Growth	2,065.3%
Net Debt Equity	$-1.49
Tangible Book Value	$30.3M
Tangible Book Value Per Share	$2.67
WACC	16.52

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.87
Net Working Capital	$-15.8M
Quick ratio	2.86
Working Capital	$30.4M
Working Capital Turnover	$0.06

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-213.01%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-96.48%
1Y total return	359.87%
200-day SMA	8.26
3Y total return	-76.33%
50-day SMA	9.58
50-day SMA vs 200-day SMA	50over200
5Y total return	-97.13%
All Time High	31,900
All Time High Change	-99.95%
All Time High Date	2003-12-08
All Time Low	2.86
All Time Low Change	404.9%
All Time Low Date	2025-04-17
ATR	1.17
Beta	2.23
Beta1y	1.34
Beta2y	2.11
Ch YTD	109.6
High	14.8
High52	17.4
High52 Date	2025-12-08
High52ch	-17.01%
Low	13.3
Low52	3.05
Low52 Date	2025-05-08
Low52ch	373.44%
Ma50ch	50.73%
Price vs 200-day SMA	74.84%
RSI	72.31
RSI Monthly	42.3
RSI Weekly	67.37
Sharpe ratio	1.63x
Sortino ratio	3.39
Total Return	-213.01%
Tr YTD	109.6
Tr15y	-96.95%
Tr1m	50.1%
Tr1w	7.84%
Tr3m	149.4%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	1
Analyst Price Target Top	$18
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Operating Income	$-12.2M
Operating margin	-964.2
Price target	$19.5
Price Target Change	$35.04
Price Target Change Top	$24.65

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	7,892,018%
Float Percent	69.07%
Shares Insiders	14%
Shares Institutions	15.74%
Shares Out	11,426,899
Shares Qo Q	132.62%
Shares Yo Y	213.01%
Short Ratio	1.08
Short Shares	1.63

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-13.7M
Average Volume	312,733.05x
Bv Per Share	2.73
Ch10y	-96.48
Ch15y	-99
Ch1m	50.1
Ch1w	7.84
Ch1y	359.9
Ch20y	-99.89
Ch3m	149.4
Ch3y	-76.33
Ch5y	-97.13
Ch6m	97
Change	7.68%
Change From Open	5.48
Close	13.41
Days Gap	2.09
Depreciation Amortization	338,106.2
Dollar Volume	5,579,673.8
Earnings Date	2026-06-04
Earnings Time	bmo
EBIT	$-12.2M
EBITDA	$-11.9M
EPS	$-6.82
F Score	2
FCF	$-10.4M
FCF EV Yield	-8.79x
FCF Per Share	$-0.91
Financing CF	54,404,826
Fiscal Year End	June
Founded	1,994
Income Tax	$-1.1M
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2025-11-07
Last Report Date	2025-12-31
Last Split Date	2025-04-17
Last Split Type	Reverse
Ma150	8.36
Ma150ch	72.81%
Ma20	11.9
Ma20ch	21.32%
Net CF	44,287,926
Next Earnings Date	2026-06-04
Open	13.69
Optionable	Yes
Position In Range	76
Post Close	14.44
Postmarket Change Percent	1.94
Postmarket Price	$14.72
Price Date	2026-05-08
Ptbv Ratio	5.45
Relative Volume	1.24x
Revenue	1,266,429x
SBC By Revenue	254.04x
Share Based Comp	3,217,261
Tax By Revenue	-84.82x
Tr20y	-99.66%
Tr6m	97%
Volume	386,404
Z Score	-2.53

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does KZIA pay a dividend?

Capital-return profile for this ticker.

Performance

KZIA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns KZIA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+15.7%

Float: +69.1% of shares outstanding

Insider ownership

+14.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

KZIA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

72.3

Above 70: short-term overbought

Price vs 200-day MA

+74.8%

50/200-day relationship not available

Beta (5Y)

2.23

More volatile than the market

Sharpe ratio

1.63

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About KZIA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current KZIA stock rating?

Kazia Therapeutics Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full KZIA analysis?

The full report lives at /stocks/KZIA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for KZIA?

The latest report frames KZIA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the KZIA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.